SeaStar Medical Holding Corporation has announced positive preliminary results from its SAVE Surveillance Registry, evaluating the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in pediatric patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy. The results were presented at the 5th International Symposium on Acute Kidney Injury in Children. Data from the first 21 pediatric patients showed no device-related adverse events or infections and no reports of immunosuppressive effects. Survival rates were reported at 76% for both Day 28 and Day 60, and 71% at Day 90. The SAVE Registry is designed to collect real-world evidence from up to 300 patients and aims to confirm the safety and efficacy of QUELIMMUNE therapy. SeaStar Medical plans to use these findings to support broader adoption of the therapy and to inform ongoing clinical trials in adult populations.